Published in Am J Med on September 01, 1984
Antibiotic combinations: should they be tested? Clin Microbiol Rev (1988) 2.34
Imipenem therapy of Pseudomonas aeruginosa and other serious bacterial infections. Antimicrob Agents Chemother (1984) 1.20
Comparative activities of piperacillin, ceftazidime, and amikacin, alone and in all possible combinations, against experimental Pseudomonas aeruginosa infections in neutropenic rats. Antimicrob Agents Chemother (1985) 1.17
Imipenem-cilastatin as initial therapy for febrile cancer patients. Antimicrob Agents Chemother (1986) 1.05
Imipenem-induced resistance to antipseudomonal beta-lactams in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1985) 1.03
Synergism of the combinations of imipenem plus ciprofloxacin and imipenem plus amikacin against Pseudomonas aeruginosa and other bacterial pathogens. Antimicrob Agents Chemother (1987) 1.03
Antimicrobial agent therapy for Pseudomonas aeruginosa. Antimicrob Agents Chemother (1991) 1.02
Gram-positive superinfections following beta-lactam chemotherapy: the significance of the enterococcus. Infection (1985) 1.02
Effects of beta-lactam antibiotics on proliferating eucaryotic cells. Antimicrob Agents Chemother (1987) 0.92
Changes in endogenous microflora among febrile granulocytopenic patients receiving empiric antibiotic therapy: implications for fungal superinfection. CMAJ (1987) 0.77
New developments in the treatment of gram-negative bacteremia. West J Med (1986) 0.76
Do double-beta-lactam combinations prolong neutropenia in patients undergoing chemotherapy or bone marrow transplantation for hematological disease? Antimicrob Agents Chemother (1989) 0.75
[A comparative review of combination therapy: 2 beta-lactams versus beta-lactam plus aminoglycoside]. Infection (1987) 0.75
Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature (1985) 8.32
Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet (2001) 7.31
Graft-versus-leukemia reactions after bone marrow transplantation. Blood (1990) 7.11
Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J (1987) 6.26
A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med (1992) 6.06
Immunotyping of Chlamydia trachomatis with monoclonal antibodies. J Infect Dis (1985) 5.29
Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet (1991) 4.76
Mycobacterial infections in AIDS patients, with an emphasis on the Mycobacterium avium complex. Rev Infect Dis (1987) 4.54
IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol (1997) 4.52
Tumor necrosis factor, alone or in combination with IL-2, but not IFN-gamma, is associated with macrophage killing of Mycobacterium avium complex. J Immunol (1988) 4.47
Severe candidal infections: clinical perspective, immune defense mechanisms, and current concepts of therapy. Ann Intern Med (1978) 4.15
Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J Virol (1994) 4.08
Simple method for elimination of aminoglycosides from serum to permit bioassay of other antimicrobial agents. Antimicrob Agents Chemother (1977) 3.91
Aspergillosis complicating neoplastic disease. Am J Med (1973) 3.80
Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene. Cell (1986) 3.59
Influence of the Epstein-Barr virus nuclear antigen EBNA 2 on the growth phenotype of virus-transformed B cells. J Virol (1987) 3.53
Bone marrow transplantation after the Chernobyl nuclear accident. N Engl J Med (1989) 3.46
Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol (1992) 3.41
Cord-blood-cell transplantation--a real sleeper? N Engl J Med (1995) 3.29
Monoclonal antibodies to the latent membrane protein of Epstein-Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells. J Gen Virol (1987) 3.28
Human immunity to Pseudomonas aeruginosa. I. In-vitro interaction of bacteria, polymorphonuclear leukocytes, and serum factors. J Infect Dis (1972) 3.28
Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol (1990) 3.19
Determination of in vitro susceptibility of Mycobacterium avium complex isolates to antimycobacterial agents by various methods. Antimicrob Agents Chemother (1987) 3.06
Hemagglutination typing of Escherichia coli: definition of seven hemagglutination types. J Clin Microbiol (1980) 3.03
Hematologic abnormalities in Fanconi anemia: an International Fanconi Anemia Registry study. Blood (1994) 2.93
Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med (1993) 2.90
Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol (1999) 2.88
Activity of five aminoglycoside antibiotics in vitro against gram-negative bacilli and Staphylococcus aureus. Antimicrob Agents Chemother (1973) 2.85
Hemolysin and K antigens in relation to serotype and hemagglutination type of Escherichia coli isolated from extraintestinal infections. J Clin Microbiol (1981) 2.82
In vitro studies of piperacilin, a new semisynthetic penicillin. Antimicrob Agents Chemother (1978) 2.82
Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol (1997) 2.79
Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med (2000) 2.78
Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation. Nature (1990) 2.72
Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood (1999) 2.65
Epstein-Barr virus infection and replication in a human epithelial cell system. Nature (1992) 2.62
Epstein-Barr virus persistence and virus-associated tumours. Lancet (1994) 2.60
Tobramycin (nebramycin factor 6): in vitro activity against Pseudomonas aeruginosa. Appl Microbiol (1971) 2.60
Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J Exp Med (1993) 2.56
Confirmation of the beige mouse model for study of disseminated infection with Mycobacterium avium complex. J Infect Dis (1986) 2.56
Nontuberculous mycobacterial infections: a clinical review. Infection (2004) 2.56
Septicemia due to Aeromonas hydrophila: clinical and immunologic aspects. J Infect Dis (1973) 2.55
Coagulase-negative staphylococcal bacteremia in patients receiving immunosuppressive therapy. Arch Intern Med (1983) 2.53
HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry. Ann Intern Med (1996) 2.52
Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man. J Clin Invest (1979) 2.50
Treatment of disseminated Mycobacterium avium complex infection in AIDS with amikacin, ethambutol, rifampin, and ciprofloxacin. California Collaborative Treatment Group. Ann Intern Med (1990) 2.45
Beta-lactam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone. Ann Intern Med (1991) 2.41
Comparison of methods for assessing in vitro antibiotic synergism against Pseudomonas and Serratia. J Lab Clin Med (1975) 2.41
Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol (1997) 2.36
In vitro evaluation of opsonic and cellular granulocyte function by luminol-dependent chemiluminescence: utility in patients with severe neutropenia and cellular deficiency states. Infect Immun (1978) 2.33
Radioimmunoassay, acetylating radio-enzymatic assay, and microbioassay of gentamicin: a comparative study. J Lab Clin Med (1975) 2.30
Clinical uses of intravenous immunoglobulins. Ann Intern Med (1990) 2.29
Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality. Blood (1976) 2.29
T-cell depletion of HLA-identical transplants in leukemia. Blood (1991) 2.25
Distinction between Epstein-Barr virus type A (EBNA 2A) and type B (EBNA 2B) isolates extends to the EBNA 3 family of nuclear proteins. J Virol (1989) 2.23
Nocardia asteroides infection complicating neoplastic disease. Am J Med (1971) 2.23
Comparative in vitro activity of moxalactam, cefotaxime, cefoperazone, piperacillin, and aminoglycosides against gram-negative bacilli. Antimicrob Agents Chemother (1980) 2.23
Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1). Oncogene (1998) 2.22
Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man. J Exp Med (1991) 2.20
A short 5' flanking region containing conserved sequences is required for silkworm alanine tRNA gene activity. Proc Natl Acad Sci U S A (1983) 2.19
Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production. J Biol Chem (1999) 2.17
1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis (1997) 2.14
Piperacillin therapy for serious bacterial infections. Am J Med (1980) 2.14
Multicenter comparative evaluation of two rapid microscopic methods and culture for detection of Chlamydia trachomatis in patient specimens. J Clin Microbiol (1988) 2.12
Genes on chromosomes 4, 9, and 19 involved in 11q23 abnormalities in acute leukemia share sequence homology and/or common motifs. Proc Natl Acad Sci U S A (1993) 2.12
Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood (1993) 2.12
Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis (1996) 2.12
A simultaneous outbreak of meningococcal and influenza infections. N Engl J Med (1972) 2.11
Trimethoprim-sulfamethoxazole for the treatment of Pneumocystis carinii pneumonia. Ann Intern Med (1980) 2.11
Is there a T-cell form of chronic lymphocytic leukemia? Leukemia (1992) 2.08
Controlled trials of amphotericin B lipid complex and other lipid-associated formulations. Clin Infect Dis (2000) 2.05
Treatment of cytomegalovirus retinopathy with ganciclovir. Ophthalmology (1987) 2.03
Chronic myelogenous leukemia: recent advances. Blood (1985) 1.99
What's new in blood progenitor cell autotransplants? Bone Marrow Transplant (1994) 1.98
Polymorphonuclear leukocytes in antibody-dependent cellular cytotoxicity. J Immunol (1975) 1.98
Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood (1990) 1.98
Interaction of Mycobacterium avium complex with human macrophages: roles of membrane receptors and serum proteins. Infect Immun (1991) 1.97
Treatment of experimental disseminated Mycobacterium avium complex infection in mice with recombinant IL-2 and tumor necrosis factor. J Immunol (1989) 1.92
Gram-negative rod bacteremia: microbiologic, immunologic, and therapeutic considerations. Ann Intern Med (1977) 1.90
Cloning of the ALL-1 fusion partner, the AF-6 gene, involved in acute myeloid leukemias with the t(6;11) chromosome translocation. Cancer Res (1993) 1.89
Antimicrobial synergism in the therapy of gram-negative rod bacteremia. Chemotherapy (1978) 1.88
Transcripts from the Epstein-Barr virus BamHI A fragment are detectable in all three forms of virus latency. J Virol (1993) 1.88
Epstein-Barr virus receptors on human pharyngeal epithelia. Lancet (1986) 1.88
Comparative efficacy and toxicity of amikacin/carbenicillin versus gentamicin/carbenicillin in leukopenic patients: a randomized prospective trail. Am J Med (1977) 1.86
CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr Virus-encoded LMP1: involvement of TRAF3 as a common mediator. Oncogene (1996) 1.85
Outcome of bone marrow transplantation patients requiring mechanical ventilation. Crit Care Med (2000) 1.85